<DOC>
	<DOCNO>NCT03001596</DOCNO>
	<brief_summary>The purpose study evaluate outcome neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy follow minimally invasive esophagectomy patient locally advance resectable esophageal squamous cell carcinoma ( cT3-4aN0-1M0 ) .</brief_summary>
	<brief_title>Comparison Between NCRT NCT Followed MIE Treatment Locally Advanced Resectable ESCC</brief_title>
	<detailed_description>It prospective randomize phase III clinical trial sponsor Shanghai Zhongshan Hospital eight hospital China participate . 264 patient locally advance resectable esophageal squamous cell carcinoma ( cT3-4aN0-1M0 ) recruit randomly assign neoadjuvant chemoradiotherapy group ( NCRT group ) neoadjuvant chemotherapy group ( NCT group ) accord proportion 1:1.The safety , efficacy protocol prognosis patient compare two regimen .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<criteria>1 . Histologicallyconfirmed squamous cell carcinoma esophagus ; 2 . Tumors esophagus locate thoracic cavity ; 3 . Pretreatment stage cT34aN01M0 ( AJCC/UICC 7th Edition ) ( In case stage cT4a , curative resectability explicitly verify local surgical investigator prior randomization ) . 4 . Age 18 year 75 year , 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status 01 ; 6 . Adequate cardiac function . All patient perform ECG , cardiac history ECG abnormality perform echocardiography leave ventricular ejection fraction &gt; 50 % . 7 . Adequate respiratory function FEV1≥1.2L , FEV1 % ≥50 % DLCO≥50 % show pulmonary function test . 8 . Adequate bone marrow function ( White Blood Cells &gt; 4x10^9 /L ; Neutrophil &gt; 2.0×10^9 /L ; Hemoglobin &gt; 90 g/L ; platelet &gt; 100x10^9 /L ) ; 9 . Adequate liver function ( Total bilirubin &lt; 1.5x Upper Level Normal ( ULN ) ; Aspartate transaminase ( AST ) Alanine transaminase ( ALT ) &lt; 1.5x ULN ) ; 10 . Adequate renal function ( Glomerular filtration rate ( CCr ) &gt; 60 ml/min ; serum creatinine ( SCr ) ≤120 µmol/L ) ； 11 . The patient provide write informed consent able understand comply study ; 1 . Patients nonsquamous cell carcinoma histology ; 2 . Patients advance inoperable metastatic esophageal cancer ; 3 . Pretreatment stage cT12N01M0 ( AJCC/UICC 7th Edition ) ; 4 . Pretreatment stage cN23 cT4b ( noncurativelyresectable verify local surgical investigator , AJCC/UICC 7th Edition ) ; 5 . Patients another previous current malignant disease likely interfere treatment assessment response judgement local surgical investigator . 6 . Any patient significant medical condition think unlikely tolerate therapy . Such cardiac disease ( e.g . symptomatic coronary artery disease myocardial infarction within last 12 month ) , clinicallysignificant lung disease , clinicallysignificant bone marrow , liver , renal function disorder ; 7 . Pregnant lactate woman fertile woman use contraception trial ; 8 . Allergy drug ; 9 . Participation another intervention clinical trial interference chemotherapeutic chemoradiotherapeutic intervention study last 30 day prior informed consent ; 10 . Expected lack compliance protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Neoadjuvant Chemoradiotherapy</keyword>
	<keyword>Neoadjuvant Chemotherapy</keyword>
	<keyword>Minimally Invasive Esophagectomy</keyword>
	<keyword>Esophageal Squamous Cell Carcinoma（cT3-4aN0-1M0）</keyword>
</DOC>